

Special Issue

Precision Medicine in Urologic Oncology: Diagnosis, Treatment and Prognosis

Message from the Guest Editor

Malignant tumors emerging from the urinary tract make up a significant part of all human neoplastic diseases, with prostate cancer being the second most commonly diagnosed malignancy among men worldwide. Because of their aggressive clinical course and substantial burden for both healthcare systems and for individual patients, every effort should be undertaken to develop more precise diagnostic methods and more effective therapeutic modalities. In this Special Issue of *JPM*, we present a series of high-quality original articles and meta-analyses concerning various urologic malignancies, illustrating the current developments in both diagnosis and treatment.

Guest Editor

Dr. Wojciech Krajewski

Department of Urology and Oncologic Urology, Wrocław Medical University, 50-556 Wrocław, Poland

Deadline for manuscript submissions

closed (15 July 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/92211

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).